Taxus Cardium Pharmaceuticals Financials

CRXMDelisted Stock  USD 0.0001  0.00  0.00%   
We advise to exercise Taxus Cardium fundamental analysis to find out if markets are presently mispricing the firm. In other words you can harness it to find out if Taxus Cardium Pharma is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We have analyzed and interpolated twenty-nine available drivers for Taxus Cardium Pharmaceuticals, which can be compared to its competition. The stock experiences a normal downward fluctuation but is a risky buy. Check odds of Taxus Cardium to be traded at $1.0E-4 in 90 days.
  
Understanding current and past Taxus Cardium Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Taxus Cardium's financial statements are interrelated, with each one affecting the others. For example, an increase in Taxus Cardium's assets may result in an increase in income on the income statement.

Taxus Cardium Stock Summary

Taxus Cardium competes with Revolution Medicines, Blueprint Medicines, Sana Biotechnology, Kymera Therapeutics, and Monte Rosa. Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California. Taxus Cardium operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
InstrumentUSA Pink Sheet View All
ExchangePINK Exchange
ISINUS8767671048
Business Address11230 Sorrento Valley
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitegenebiotherapeutics.com
Phone858 414 1477
CurrencyUSD - US Dollar

Taxus Cardium Key Financial Ratios

There are many critical financial ratios that Taxus Cardium's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Taxus Cardium Pharma reports annually and quarterly.

Taxus Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Taxus Cardium's current stock value. Our valuation model uses many indicators to compare Taxus Cardium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Taxus Cardium competition to find correlations between indicators driving Taxus Cardium's intrinsic value. More Info.
Taxus Cardium Pharmaceuticals is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taxus Cardium's earnings, one of the primary drivers of an investment's value.

Taxus Cardium Market Pulse

 Quote1.0E-4
 Change(%) 0.00  
 Change0.00 
 Open1.0E-4
 Low1.0E-4
 High1.0E-4
 Volume0
 ExchangePINK
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Taxus Pink Sheet

If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Valuation
Check real value of public entities based on technical and fundamental data